KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Leases: 2011-2025

Historic Current Leases for Nektar Therapeutics (NKTR) over the last 10 years, with Sep 2025 value amounting to $22.2 million.

  • Nektar Therapeutics' Current Leases rose 3.16% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 3.16%. This contributed to the annual value of $19.9 million for FY2024, which is 3.16% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Current Leases stood at $22.2 million, which was up 0.78% from $22.0 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Current Leases registered a high of $22.2 million during Q3 2025, and its lowest value of $15.8 million during Q1 2021.
  • In the last 3 years, Nektar Therapeutics' Current Leases had a median value of $19.9 million in 2024 and averaged $20.4 million.
  • In the last 5 years, Nektar Therapeutics' Current Leases rose by 25.34% in 2021 and then decreased by 5.56% in 2023.
  • Nektar Therapeutics' Current Leases (Quarterly) stood at $17.4 million in 2021, then grew by 7.03% to $18.7 million in 2022, then climbed by 3.17% to $19.3 million in 2023, then climbed by 3.16% to $19.9 million in 2024, then grew by 3.16% to $22.2 million in 2025.
  • Its Current Leases stands at $22.2 million for Q3 2025, versus $22.0 million for Q2 2025 and $21.8 million for Q1 2025.